Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKinsey
Dow
AstraZeneca
Boehringer Ingelheim

Last Updated: February 1, 2023

Details for Patent: 9,597,409


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 9,597,409 protect, and when does it expire?

Patent 9,597,409 protects ABRAXANE and is included in one NDA.

Protection for ABRAXANE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in twenty-three countries.

Summary for Patent: 9,597,409
Title:Methods of treating cancer
Abstract: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:13/782,990
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,597,409
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 9,597,409

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol-myers ABRAXANE paclitaxel POWDER;INTRAVENOUS 021660-001 Jan 7, 2005 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,597,409

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011235344 See Plans and Pricing
Australia 2016202000 See Plans and Pricing
Brazil 112012024442 See Plans and Pricing
Canada 2793974 See Plans and Pricing
Canada 3087813 See Plans and Pricing
China 103118665 See Plans and Pricing
Costa Rica 20120528 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Johnson and Johnson
McKinsey
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.